Multiple Reaction Monitoring-Based Targeted Assays for the Validation of Protein Biomarkers in Brain Tumors
Proteomics
FOS: Computer and information sciences
targeted proteomics
multiple reaction monitoring
S100 Proteins: Structure, Function, and Pathology
Protein Identification
Proteome
Bioinformatics
Tandem mass spectrometry
Omics
Apoptosis
Cancer research
Biochemistry
Gene
Mass Spectrometry
Computational biology
03 medical and health sciences
Tandem Mass Spectrometry
Biochemistry, Genetics and Molecular Biology
Health Sciences
Quantitative proteomics
Molecular Biology
Biology
RC254-282
Spectroscopy
Chromatography
0303 health sciences
Role of Clusterin in Cancer and Disease
Mass spectrometry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Life Sciences
Glioma
Mass Spectrometry Techniques with Proteins
3. Good health
gliomas
Chemistry
Clusterin
Oncology
Calcium Modulated Proteins
Physical Sciences
Selected reaction monitoring
Medicine
Meningioma
Medulloblastoma
DOI:
10.3389/fonc.2021.548243
Publication Date:
2021-05-14T14:37:45Z
AUTHORS (12)
ABSTRACT
The emergence of omics technologies over the last decade has helped in advancement research and our understanding complex diseases like brain cancers. However, barring genomics, no other technology been able to find utility clinical settings. recent advancements mass spectrometry instrumentation have resulted proteomics becoming more sensitive reliable. Targeted proteomics, a relatively new branch spectrometry-based shown immense potential addressing shortcomings standard molecular biology-based techniques Western blotting Immunohistochemistry. In this study we demonstrate Multiple reaction monitoring (MRM), targeted approach, quantifying peptides from proteins Apolipoprotein A1 (APOA1), E (APOE), Prostaglandin H2 D-Isomerase (PTGDS), Vitronectin (VTN) Complement C3 (C3) cerebrospinal fluid (CSF) collected Glioma Meningioma patients. Additionally, also report transitions for - Vimentin (VIM), Cystatin-C (CST3) Clusterin (CLU) surgically resected tissues; Annexin (ANXA1), Superoxide dismutase (SOD2) VIM Microtubule associated protein-2 (MAP-2), Splicing factor 3B subunit 2 (SF3B2) Medulloblastoma tissues. To knowledge, is first reporting use MRM validate three types malignancies two different bio-specimens. Future studies involving large cohort samples aimed at accurately detecting with roles could potentially result panel showing ability classify grade tumors. Successful application these ultimately offer alternative strategies increased accuracy, sensitivity lower turnaround time making them translatable clinics.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....